Ketanserin is a 5-HT 2 receptor antagonist without partial agonist properties which also
possesses weak α 1-adrenoceptor antagonistic activity, which may explain its …

The pharmacokinetics of ketanserin (R 41468), a novel serotonin S 2-receptor blocking
agent widely investigated for its effect on acute and chronic hypertension, has been studied …

Ketanserin is a new, specific serotonin receptor blocking agent, which causes
vasodilatation, presumably by an action on the vascular wall. The antihypertensive response …

Extensive clinical investigation has shown that ketanserin is an effective first‐line
antihypertensive agent with particular advantages in older patients. It has a favorable …

The pharmacokinetics of ketanserin and its main metabolite ketanserin-ol, and the
antihypertensive effects of intravenous, single oral and chronic oral (40 mg once daily) …

Ketanserin is a serotonin (S,) Mocker that reduces blood pressure (BP) in patients with
essential hypertension preferentially by a reduction of peripheral vascular resistance. Heart …

Ketanserin is an agent whose main pharmacologic action is antagonism of serotonin (5-
hydroxytryptamine, 5HT) receptors of the 5HT2 subtype. It also has weak α1-adrenergic …

Ketanserin is a serotonin S 2-receptor antagonist introduced for the treatment of arterial
hypertension and vasospastic disorders. Plasma concentrations of ketanserin (and some …

The antihypertensive effect of the selective serotonin antagonist ketanserin was examined in
a double-blind, placebo-controlled, parallel group study in 20 patients with essential …

Abstract Ketanserin (3× 40 mg daily) was administered during 6 weeks in 14 patients with
mild to moderate essential hypertension using a double-blind, placebo-controlled, crossover …